Skip to main content
News Icon

Publication

Study for treatment of lymphatic filariosis in Science Translational Medicine published

Neglected tropical diseases such as Lymphatic filariosis are common in tropical and subtropical areas. Here mostly poor people are affected.
An international consortium with a contribution of scientists from the Cluster of Excellence ImmunoSensation identified a new substance ABBV-4083 in the fight against adult worms, the cause of lymphatic filariosis.
Dr. Marc Hübner and Prof. Hörauf are working in the Institute of Medical Microbiology, Immunology and Parasitology at the University Hospital Bonn.


Publication

Mark J. Taylor, Thomas W. von Geldern, Louise Ford, Marc P. Hübner, Kennan Marsh, Kelly L. Johnston, Hanna T. Sjoberg, Sabine Specht, Nicolas Pionnier, Hayley E. Tyrer, Rachel H. Clare, Darren A. N. Cook, Emma Murphy, Andrew Steven, John Archer, Dominique Bloemker, Franziska Lenz, Marianne Koschel, Alexandra Ehrens, Haelly M. Metuge, Valerinne C. Chunda, Patrick W. Ndongmo Chounna, Abdel J. Njouendou, Fanny F. Fombad, Robert Carr, Howard E. Morton, Ghaith Aljayyoussi, Achim Hoerauf, Samuel Wanji, Dale J. Kempf, Joseph D. Turner, Stephen A. Ward: Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis, Science Translational Medicine, DOI: 10.1126/scitranslmed.aau2086

Related news

News Icon

Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

—A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

Publication

Driver of inflammation after mild head injury

—Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

Publication

Study reveals dynamic interactions between brain tumors and immune cells

—Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry

Back to the news overview